100 Participants Needed

IV Saline for POTS and Long COVID

SR
TS
RH
Overseen ByRasha Hamzeh, RN
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: University of Calgary
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial may require you to stop taking certain medications if they could interfere with the test results, but it doesn't specify which ones. It's best to discuss your current medications with the trial team to see if any changes are needed.

Is IV saline generally safe for humans?

The research articles provided do not contain relevant safety information about IV saline for humans.12345

How does the IV saline treatment for POTS and Long COVID differ from other treatments?

IV saline treatment is unique because it involves administering a large volume (999 mL) of normal saline directly into the bloodstream, which can help improve blood volume and circulation. This approach is different from oral medications or lifestyle changes typically used for POTS and Long COVID, as it provides immediate hydration and electrolyte balance.678910

What is the purpose of this trial?

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).

Research Team

SR

Satish R Raj, MD MSCI

Principal Investigator

University of Calgary

Eligibility Criteria

This trial is for adults aged 18-60 with Long COVID or Postural Orthostatic Tachycardia Syndrome (POTS) who experience 'brain fog' or cognitive issues. Healthy individuals without POTS or brain fog can also participate. People must have had a positive SARS-CoV-2 test and symptoms persisting over 12 weeks.

Inclusion Criteria

I am either male or female.
I have been diagnosed with Long COVID.
SARS-COV2 test positive
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either 999 mL or 50 mL of normal saline intravenously, followed by cognitive and physiological testing

3 hours
2 visits (in-person)

Follow-up

Participants complete a series of validated questionnaires to assess psychiatric symptoms

1 week
Online survey

Treatment Details

Interventions

  • IV normal saline (50 mL infusion)
  • IV normal saline (999 mL infusion)
Trial Overview The study tests if giving patients with POTS and Long COVID a large volume of IV saline (999 mL) improves their cognitive function compared to a much smaller dose (50 mL, considered as placebo).
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 999 mL normal SalineExperimental Treatment1 Intervention
999 mL of normal saline infused intravenously.
Group II: 50 mL normal SalinePlacebo Group1 Intervention
50 mL of normal saline infused intravenously.

IV normal saline (999 mL infusion) is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Normal Saline for:
  • Dehydration
  • Hypovolemia
  • Shock
  • Metabolic acidosis
  • Hyponatremia
  • Hypernatremia
  • Fluid replacement
  • Electrolyte disturbances
🇪🇺
Approved in European Union as Sodium Chloride for:
  • Dehydration
  • Hypovolemia
  • Shock
  • Metabolic acidosis
  • Hyponatremia
  • Hypernatremia
  • Fluid replacement
  • Electrolyte disturbances
🇨🇦
Approved in Canada as Normal Saline for:
  • Dehydration
  • Hypovolemia
  • Shock
  • Metabolic acidosis
  • Hyponatremia
  • Hypernatremia
  • Fluid replacement
  • Electrolyte disturbances

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Calgary

Lead Sponsor

Trials
827
Recruited
902,000+

Findings from Research

A new liquid suppository system using sodium chloride and poloxamers was developed for diclofenac sodium, which was easier to administer and showed no leakage after insertion, unlike previous formulations with bioadhesive polymers that caused drug precipitation.
The liquid suppository demonstrated significantly higher initial plasma concentrations and faster absorption of diclofenac sodium compared to solid suppositories, indicating it is a more effective and convenient rectal dosage form.
Physicochemical characterization and in vivo evaluation of thermosensitive diclofenac liquid suppository.Yong, CS., Choi, YK., Kim, YI., et al.[2019]
The thermosensitive poloxamer gel loaded with diclofenac sodium showed faster absorption and higher initial plasma concentrations in rats compared to traditional semi-solid suppositories, indicating improved efficacy for rectal delivery.
The formulation was safe, as it did not cause any morphological damage to rectal tissues, suggesting that poloxamer gels with sodium chloride could be a safer alternative for delivering diclofenac sodium rectally.
Effect of sodium chloride on the release, absorption and safety of diclofenac sodium delivered by poloxamer gel.Park, YJ., Yong, CS., Kim, HM., et al.[2019]
In a study involving 42 healthy adults, intravenous diclofenac sodium (DFP-08) at doses of 18.75 mg and 37.5 mg showed similar exposure levels to a 50 mg oral diclofenac potassium tablet, indicating effective absorption and dose proportionality.
The intravenous formulation was well tolerated over 7 days, with only mild adverse events reported, suggesting a favorable safety profile, although further studies are needed to fully assess its efficacy and safety.
Safety and pharmacokinetics of single and multiple intravenous bolus doses of diclofenac sodium compared with oral diclofenac potassium 50 mg: A randomized, parallel-group, single-center study in healthy subjects.Munjal, S., Gautam, A., Okumu, F., et al.[2016]

References

Physicochemical characterization and in vivo evaluation of thermosensitive diclofenac liquid suppository. [2019]
Effect of sodium chloride on the release, absorption and safety of diclofenac sodium delivered by poloxamer gel. [2019]
Safety and pharmacokinetics of single and multiple intravenous bolus doses of diclofenac sodium compared with oral diclofenac potassium 50 mg: A randomized, parallel-group, single-center study in healthy subjects. [2016]
Antipyretic therapy in ICU patients: evaluation of low dose diclofenac sodium. [2019]
Control of fever by continuous, low-dose diclofenac sodium infusion in acute cerebral damage patients. [2019]
Taste and Odour Disturbances in Pediatric Patients Undergoing IV Flush with Normal Saline Administered by Prefilled or Freshly Prepared Syringes: Randomized Single-Blind Study. [2019]
Long-Term Outcome Assessment Between Antiseptic and Normal Saline for Negative Pressure Wound Therapy with Instillation. [2021]
The Impact of Normal Saline or Balanced Crystalloid on Plasma Chloride Concentration and Acute Kidney Injury in Patients With Predicted Severe Acute Pancreatitis: Protocol of a Phase II, Multicenter, Stepped-Wedge, Cluster-Randomized, Controlled Trial. [2021]
Hypertonic saline resuscitation: efficacy in a community-based burn unit. [2013]
Long-term outcomes of saline boluses in very preterm infants. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security